50 Best Peptides

This website is for informational purposes only and does not constitute medical advice. Read disclaimer

#64

Degarelix

Reproductive HealthFirmagonDegarelix Acetate

A next-generation GnRH antagonist approved for advanced prostate cancer, providing immediate testosterone suppression without flare while offering a favorable safety profile compared to earlier GnRH antagonists.

Share:

Overview

Degarelix is a synthetic decapeptide GnRH receptor antagonist developed by Ferring Pharmaceuticals and approved by the FDA in 2008 for the treatment of advanced prostate cancer. It represents a significant improvement over the first-generation GnRH antagonist abarelix, offering immediate testosterone suppression without hormonal flare and with a substantially lower risk of systemic allergic reactions.

Degarelix works by directly and competitively blocking GnRH receptors on pituitary gonadotrope cells, immediately suppressing the release of LH and FSH. This results in rapid testosterone suppression to castrate levels, typically achieved within 3 days of the initial loading dose — significantly faster than GnRH agonists, which require 2-4 weeks. The absence of flare eliminates the need for concurrent anti-androgen therapy that is typically required during the initiation of GnRH agonist treatment.

The pivotal CS21 trial demonstrated that degarelix achieved castrate testosterone levels in 99% of patients by day 3 and maintained suppression in over 97% of patients at 12 months. Additionally, post-hoc analyses and subsequent studies have suggested potential cardiovascular advantages of degarelix over GnRH agonists, with some data indicating lower rates of cardiovascular events, though this remains an area of active investigation.

Degarelix is administered as a subcutaneous injection that forms a depot at the injection site, providing sustained drug release over 28 days. The initial loading dose is higher (240 mg) and given as two injections, with subsequent monthly maintenance doses of 80 mg as a single injection. A common limitation is injection site reactions, which occur in approximately 40% of patients but are generally mild to moderate.

Research Uses & Applications

  • First-line treatment of advanced prostate cancer requiring androgen deprivation
  • Patients requiring immediate testosterone suppression without hormonal flare
  • Prostate cancer patients with cardiovascular risk factors (based on emerging data)
  • Pre-radiation androgen deprivation for intermediate-risk prostate cancer
  • Neoadjuvant hormonal therapy before radical prostatectomy
  • Research into GnRH antagonist cardiovascular effects

Key Research Findings

  • The CS21 trial showed degarelix achieved testosterone <50 ng/dL in 99% of patients by day 3, versus 18% for leuprolide (NEJM, 2008).
  • Post-hoc analysis of pooled data suggested a 56% reduction in cardiovascular events with degarelix versus GnRH agonists in patients with pre-existing cardiovascular disease.
  • Studies demonstrated rapid PSA decline with degarelix, with median PSA reduction of 64% at 14 days versus 18% for leuprolide.
  • Research showed degarelix maintained testosterone suppression with no microsurges or breakthroughs in >97% of patients through 12 months.
  • Clinical data indicated degarelix may provide superior disease control as measured by PSA progression-free survival compared to leuprolide in a subset analysis.

Risks & Side Effects

  • Injection site reactions (pain, erythema, swelling, induration) in approximately 40% of patients, though usually mild and self-limiting.
  • Hot flashes, weight gain, and fatigue common with testosterone suppression.
  • Elevated liver enzymes reported in some patients.
  • Decreased bone mineral density with prolonged androgen deprivation.
  • Rare hypersensitivity reactions, though significantly less common than with abarelix.

Administration

Administered as subcutaneous injection in the abdominal region. Starting dose: 240 mg given as two 120 mg injections on day 1. Maintenance: 80 mg as a single subcutaneous injection every 28 days. Must be reconstituted before injection. The injection forms a subcutaneous depot for sustained release. Administered in a clinical setting.

Legal Status

FDA-approved prescription medication marketed as Firmagon. Approved for treatment of advanced prostate cancer. Available by prescription only. Approved in the US, EU, and many other countries. Not a controlled substance.

Frequently Asked Questions

What is Degarelix?

A next-generation GnRH antagonist approved for advanced prostate cancer, providing immediate testosterone suppression without flare while offering a favorable safety profile compared to earlier GnRH antagonists.

What are the main uses of Degarelix?

The primary research applications of Degarelix include: First-line treatment of advanced prostate cancer requiring androgen deprivation; Patients requiring immediate testosterone suppression without hormonal flare; Prostate cancer patients with cardiovascular risk factors (based on emerging data); Pre-radiation androgen deprivation for intermediate-risk prostate cancer; Neoadjuvant hormonal therapy before radical prostatectomy; Research into GnRH antagonist cardiovascular effects.

What are the risks and side effects of Degarelix?

Documented risks and side effects include: Injection site reactions (pain, erythema, swelling, induration) in approximately 40% of patients, though usually mild and self-limiting.; Hot flashes, weight gain, and fatigue common with testosterone suppression.; Elevated liver enzymes reported in some patients.; Decreased bone mineral density with prolonged androgen deprivation.; Rare hypersensitivity reactions, though significantly less common than with abarelix.. Always consult a healthcare professional before considering any peptide.

Is Degarelix legal?

FDA-approved prescription medication marketed as Firmagon. Approved for treatment of advanced prostate cancer. Available by prescription only. Approved in the US, EU, and many other countries. Not a controlled substance.

How is Degarelix administered?

Administered as subcutaneous injection in the abdominal region. Starting dose: 240 mg given as two 120 mg injections on day 1. Maintenance: 80 mg as a single subcutaneous injection every 28 days. Must be reconstituted before injection. The injection forms a subcutaneous depot for sustained release. Administered in a clinical setting.

Related Peptides

#23

Kisspeptin-10

Reproductive Health

#28

Oxytocin

Reproductive Health

#54

Gonadorelin

Reproductive Health

#55

Triptorelin

Reproductive Health

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Official Store

Experience Peptides on Your Skin

Shop our curated collection of peptide-infused skincare — Copper Peptide serums, anti-aging treatments, hydrogel patches, and more.

Shop Peptide Skincare

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.

← #63 Abarelix#65 Octreotide →